Yuli Qian, Eliza M Raymundo, Shuai Hao, Kristina Unnebrink, Gweneth F Levy, Henrique D Teixeira, Alvina D Chu, Zachary A Zinn, Amy S Paller, Wei Liu, Mohamed-Eslam F Mohamed
PURPOSE: This study aims to characterize the pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib, an oral Janus kinase inhibitor approved for treating moderate to severe atopic dermatitis (AD) in adults and adolescents, in children with severe AD. METHODS: In an open-label, multiple-dose, Phase 1 study, pediatric patients with severe AD from two age groups (2 to <6 years and 6 to <12 years) received bodyweight-based dosing regimens of upadacitinib using either twice-daily immediate-release (IR) oral solution or once-daily extended-release (ER) tablets...
August 13, 2024: Clinical Therapeutics